Request Sample
Request Methodology
Description
Congestive Heart Failure Treatment market size was valued at USD 19.5 billion in 2021. It is expected to reach a value of USD 31.72 billion by 2028, growing with a CAGR of 7.2% from 2022-28. Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as “heart failure”. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body’s organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure. Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs. Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market.
Key Developments:
In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction.
In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions.
